Overall , @/@ ( @ % ) patients ( @/@ tenofovir and @/@ emtricitabine/tenofovir ) completed the @-week study period , including @/@ ( @ % ) patients ( @/@ tenofovir and @/@ emtricitabine/tenofovir ) who completed the study on their initial randomized treatment .